Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CPN1 | P15169 | 1/20 | 0.42 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27567090 | 0.86 | CYP2C19 (0.47) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL8582632 | 0.83 | CYP2C19 (0.53) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL27561228 | 0.83 | EPHX1 (0.63) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL4086184 | 0.83 | CYP2C19 (0.53) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL2002439 | 0.83 | CYP2C19 (0.44) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL4795362 | 0.83 | ESR1 (0.47) | CYP2C19SRCCYP2D6LMNAPOLB | |
| SCHEMBL7973743 | 0.81 | CYP2C19 (0.61) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL30371912 | 0.81 | CYP2C19 (0.61) | CYP2C19SRCCYP2D6LMNAMAPK1 | |
| SCHEMBL12073123 | 0.81 | PTPN1 (0.44) | CYP2C19POLBALDH1A1CPN1CPB2 | |
| SCHEMBL23782080 | 0.80 | L3MBTL1 (0.59) | CYP2C19SRCCYP2D6LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190106590-A1 | COATING COMPOSITION CONTAINING A SORBIC ACID ESTER AND A PHOTOCATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2019-04-11 | — | — | US | claimed |
| EP-3440141-A1 | COATING COMPOSITION CONTAINING SORBIC ACID ESTER AND PHOTOCATALYST | Dow Global Technologies, LLC (US) | 2019-02-13 | — | — | EP | claimed |
| WO-2017173646-A1 | COATING COMPOSITION CONTAINING SORBIC ACID ESTER AND PHOTOCATALYST | DOW GLOBAL TECHNOLOGIES LLC (US) | 2017-10-12 | — | — | WO | claimed |
| CN-106905135-A | A kind of preparation method to bromomethyl phenylacetic acid | 上海应用技术大学 | 2017-06-30 | — | — | CN | claimed |
| CN-1247573-C | Method for preparing arylacetyl aminothiazole | BRISTOL MYERS SQUIBB CO (US) | 2006-03-29 | — | — | CN | claimed |
| EP-1303512-B1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL MYERS SQUIBB CO (US) | 2005-07-20 | — | — | EP | claimed |
| JP-2004505079-A | — | — | 2004-02-19 | — | — | JP | claimed |
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2003-11-20 | — | — | US | claimed |
| CN-1444583-A | Method for preparing arylacetyl aminothiazole | BRISTOL MYERS SQUIBB CO (US) | 2003-09-24 | — | — | CN | claimed |
| US-6613911-B2 | Reaction of haloarylacetic acids or esters with olefins to give vinylarylacetic acids or esters, oxidation with an oxidizing reagent gives formylarylacetic acids or esters | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | claimed |
| EP-1303512-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | Bristol-Myers Squibb Company (US) | 2003-04-23 | — | — | EP | claimed |
| WO-2003011917-A1 | METHOD OF CURING ELASTOMERS | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CHEN BANG-CHI (US) | 2002-06-13 | — | — | US | claimed |
| WO-2002010161-A1 | PROCESS FOR PREPARING ARYLACETYLAMINOTHIAZOLES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-02-07 | — | — | WO | claimed |
| EP-0906265-B1 | CHEMICAL PROCESS | SYNGENTA LTD (GB) | 2001-08-29 | — | — | EP | claimed |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | BRISTOL-MYERS SQUIBB COMPANY | 2001-06-21 | — | — | US | claimed |
| EP-4572795-A2 | METHODS AND COMPOSITIONS FOR TREATING CANCER WITH CANCER-BINDING ADJUVANTS | The University of Chicago (US) | 2025-06-25 | — | — | EP | disclosed |
| CN-116368131-B | Novel Smad3 protein degradation agent and application thereof | 和径医药科技（上海）有限公司 | 2024-09-20 | — | — | CN | disclosed |
| EP-0539066-A1 | Heterocyclic compounds useful as angiotensin II antagonists | ZENECA LIMITED (GB) | 1993-04-28 | — | — | EP | disclosed |
| EP-0452107-A1 | Pyrimidinedione derivatives and antiarrythmic agents containing same | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216440-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNT1, CCNA1 | CYP2C19 354/4885SRC 114/4885CYP2D6 332/4885 |
| US-20020072609-A1 | Process for preparing arylacetylaminothiazoles | CCNT1, CCNI, CCNA1 | CYP2C19 266/4885SRC 114/4885CYP2D6 148/4885 |
| US-20010004639-A1 | Process for preparing arylacetylaminothiazoles | CCNI, CCNA1, CCNT1 | CYP2C19 370/4885SRC 110/4885CYP2D6 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.